Published in: Joint Health

A Randomized Placebo-Controlled Dose-Response Trial of Muvz™ for Knee and Low-Back Support in Physically Active Adults

Author Swarnab

Published on: March 19, 2025

Purpose: The current study aimed to investigate the dose-response efficacy and safety of MuvzTM (E-PR-01, a blend of V. negundo
and Z. officinale) in 400 mg (High-dose [HD]) and 200 mg (Low-dose [LD]) of daily dose in physically active adults in 90 days.